Antibody Opsonization of a TLR9 Agonist–Containing Virus-like Particle Enhances In Situ Immunization

PD-L1 on host cells is essential for PD-L1 blockade–mediated tumor regression

(2018) Haidong Tang et al.   JOURNAL OF CLINICAL INVESTIGATION

CpG Still Rocks! Update on an Accidental Drug

(2018) Arthur M. Krieg   Nucleic Acid Therapeutics

Masterful Antibodies: Checkpoint Blockade

(2017) Nils Lonberg et al.   Cancer Immunology Research

Intratumoral injection of a CpG oligonucleotide reverts resistance to PD-1 blockade by expanding multifunctional CD8+T cells

(2016) Shu Wang et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Density of immunogenic antigens does not explain the presence or absence of the T-cell–inflamed tumor microenvironment in melanoma

(2016) Stefani Spranger et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Vaccination of stage III/IV melanoma patients with long NY-ESO-1 peptide and CpG-B elicits robust CD8+ and CD4+ T-cell responses with multiple specificities including a novel DR7-restricted epitope

(2016) P. Baumgaertner et al.   OncoImmunology

CYT003, a TLR9 agonist, in persistent allergic asthma - a randomized placebo-controlled Phase 2b study

(2015) T. B. Casale et al.   ALLERGY

Ibrutinib enhances the antitumor immune response induced by intratumoral injection of a TLR9 ligand in mouse lymphoma

(2015) I. Sagiv-Barfi et al.   BLOOD

Vaccination with LAG-3Ig (IMP321) and Peptides Induces Specific CD4 and CD8 T-Cell Responses in Metastatic Melanoma Patients--Report of a Phase I/IIa Clinical Trial

(2015) A. Legat et al.   CLINICAL CANCER RESEARCH

DNase II-dependent DNA digestion is required for DNA sensing by TLR9

(2015) Mei Po Chan et al.   Nature Communications

Three Steps to Breaking Immune Tolerance to Lymphoma: A Microparticle Approach

(2015) A. Makkouk et al.   Cancer Immunology Research

Biodegradable Microparticles Loaded with Doxorubicin and CpG ODN for In Situ Immunization Against Cancer

(2014) Amani Makkouk et al.   AAPS Journal

Clinical evaluation of CpG oligonucleotides as adjuvants for vaccines targeting infectious diseases and cancer

(2014) Julia Scheiermann et al.   VACCINE

Oncolytic Viruses and Their Application to Cancer Immunotherapy

(2014) E. A. Chiocca et al.   Cancer Immunology Research

A phase I trial of immunostimulatory CpG 7909 oligodeoxynucleotide and90yttrium ibritumomab tiuxetan radioimmunotherapy for relapsed B-cell non-Hodgkin lymphoma

(2013) Thomas E. Witzig et al.   AMERICAN JOURNAL OF HEMATOLOGY

PD-1 and Tim-3 Regulate the Expansion of Tumor Antigen-Specific CD8+ T Cells Induced by Melanoma Vaccines

(2013) J. Fourcade et al.   CANCER RESEARCH

Biodegradable particles as vaccine antigen delivery systems for stimulating cellular immune responses

(2013) Vijaya B Joshi et al.   Human Vaccines & Immunotherapeutics

Intratumoral delivery of CpG-conjugated anti-MUC1 antibody enhances NK cell anti-tumor activity

(2012) Jorge Schettini et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Therapeutic Applications of Nucleic Acids and Their Analogues in Toll-like Receptor Signaling

(2012) Vijayakumar Gosu et al.   MOLECULES

A phase III randomized study of gemcitabine and cisplatin with or without PF-3512676 (TLR9 agonist) as first-line treatment of advanced non-small-cell lung cancer

(2011) C. Manegold et al.   ANNALS OF ONCOLOGY

Rituximab blocks protective serologic response to influenza A (H1N1) 2009 vaccination in lymphoma patients during or within 6 months after treatment

(2011) O. E. Yri et al.   BLOOD

In situ vaccination against mycosis fungoides by intratumoral injection of a TLR9 agonist combined with radiation: a phase 1/2 study

(2011) Y. H. Kim et al.   BLOOD

Virus-like particles induce robust human T-helper cell responses

(2011) Marion Braun et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

Randomized Phase III Trial of Paclitaxel/Carboplatin With or Without PF-3512676 (Toll-Like Receptor 9 Agonist) As First-Line Treatment for Advanced Non–Small-Cell Lung Cancer

(2011) Vera Hirsh et al.   JOURNAL OF CLINICAL ONCOLOGY

In Situ Vaccination With a TLR9 Agonist Induces Systemic Lymphoma Regression: A Phase I/II Study

(2010) Joshua D. Brody et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase I trial of a Toll-like receptor 9 agonist, PF-3512676 (CPG 7909), in patients with treatment-refractory, cutaneous T-cell lymphoma

(2010) Youn H. Kim et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Generation of CD8+ T cell-mediated immunity against idiotype-negative lymphoma escapees

(2009) B. Varghese et al.   BLOOD

Use of A-type CpG oligodeoxynucleotides as an adjuvant in allergen-specific immunotherapy in humans: a phase I/IIa clinical trial

(2009) G. Senti et al.   CLINICAL AND EXPERIMENTAL ALLERGY

T-cell modulation combined with intratumoral CpG cures lymphoma in a mouse model without the need for chemotherapy

(2008) R. Houot et al.   BLOOD

NK cells stimulated with IL-15 or CpG ODN enhance rituximab-dependent cellular cytotoxicity against B-cell lymphoma

(2007) Esther Moga et al.   EXPERIMENTAL HEMATOLOGY